During the third quarter of 2014, biopharma financing declined 22% to $5.65 billion, compared with the $7.2 billion raised in Q2. (See Exhibit 1.) With $2.2 billion in deal volume, Q3 initial public offerings knocked follow-on public offerings (which brought in a total of $874 million in Q3) down from the top position, where they had been for the past two consecutive quarters.
Exhibit 1